CRBU Q3 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-91.4% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$38M-1889.2% margin

Net Income

-$35M-1713.6% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-41.6%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$344M

Total Liabilities

$63M

Stockholders' Equity

$281M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$24M	-91.4%
Gross Profit	$2M	-$5M	+141.1%
Operating Income	-$38M	-$15M	-161.3%
Net Income	-$35M	-$10M	-246.8%

Geographic Segments

UNITED STATES

$2M82%

Non-US

$367,00018%